Details checkedClinical trial listing onlyCheckedregistry

NKI SOUND transtympanic sodium thiosulfate cisplatin otoprotection study

Also known as: Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate, SOUND Trial, STS gel, M21STS, NCT07281508

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Drug Delivery

Stage

Phase 3

Status

Active

Target Gene

—

Route / Mode

Transtympanic injection

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Netherlands

Population

adult, cisplatin-ototoxicity, head-and-neck-cancer, otoprotection

Trial IDs

Mechanism

Transtympanic sodium thiosulfate gel injected into one ear before cisplatin infusion to locally prevent cisplatin-induced sensorineural hearing loss while using the untreated contralateral ear as comparator.

Indications

Hearing Loss Sensorineural Hearing Loss Cisplatin-Induced Hearing Loss Ototoxicity

Notes

Corrected from a generated intervention-name row to the NKI-led SOUND Phase 3 study. This is an active investigator-initiated cisplatin otoprotection trial and should not be presented as a company-owned product pipeline record.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT07281508, M21STS, SOUND

Open

Key Events

2025-08-14

SOUND trial started recruitment activity

2025-12-15

SOUND Phase 3 transtympanic STS study first posted on ClinicalTrials.gov

Clinical Trials (1)